Fasting hyperglycemia: Etiology, diagnosis, and treatment

Diabetes Technology and Therapeutics

Volumn 6, Issue 4, 2004, Pages 525-533

  Sheehan, John P ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Endocrinology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INSULIN GLARGINE; ISOPHANE INSULIN;

BLOOD GLUCOSE MONITORING; CIRCADIAN RHYTHM; DIAGNOSTIC ACCURACY; DIET THERAPY; DISEASE PREDISPOSITION; ENDOCRINE DISEASE; EXERCISE; FASTING HYPERGLYCEMIA; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING; VASCULAR DISEASE;

CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FASTING; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 4344659982     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/1520915041705910     Document Type: Review

References (40)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
2. Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K: Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes 2002;51:2637-2641.
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
4. Turner RC, Millns H, Neil HAW, Stratton IM, Manley SE, Matthews DR, Holman RR: Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998;316:823-828.
5. Muggeo M, Zoppini G, Bonora E, Brun E, Bonadonna RC, Moghetti P, Verlato G: Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabetes Care 2000;23:45-50.
6. DECODE Study Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397-405.
7. Skøtt P, Vaag A, Hother-Nielsen O, Andersen P, Bruun NE, Giese J, Beck-Nielsen H, Parving H-H: Effects of hyperglycaemia on kidney function, atrial natriuretic factor and plasma renin in patients with insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 1991;51:715-727.
8. De Cosmo S, Earle K, Morocutti A, Walker J, Ruggenenti P, Remuzzi G, Viberti GC: Glucose-induced changes in renal haemodynamics in proteinuric type 1 (insulin-dependent) diabetic patients: inhibition by acetylsalicilic acid infusion. Diabetologia 1993;36:622-627.
9. Thye-Rønn P, Sindrup SH, Arendt-Nielsen L, Brennum J, Hother-Nielsen O, Beck-Nielsen H: Effect of short-term hyperglycemia per se on nociceptive and non-nociceptive thresholds. Pain 1994;56:43-49.
10. Rassam SM, Patel V, Kohner EM: The effect of experimental hypertension on retinal vascular autoregulation in humans: a mechanism for the progression of diabetic retinopathy. Exp Physiol 1995;80:53-68.
11. Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A: The dawn phenomenon, an early morning glucose rise: implications for diabetic intra-day blood glucose variation. Diabetes Care 1981;4:579-585.
12. Bolli GB, Perriello G, Fanelli CG, De Feo P: Nocturnal blood glucose control in type I diabetes mellitus. Diabetes Care 1993;16(Suppl 3):71-89.
13. Bolli GB, De Feo P, De Cosmo S, Perriello G, Ventura MM, Calcinaro F, Lolli C, Campbell P, Brunetti P, Gerich JE: Demonstration of a dawn phenomenon in normal human volunteers. Diabetes 1984;33:1150-1153.
14. Bolli GB, Gerich JE: The "dawn phenomenon"-a common occurrence in both non-insulin-dependent and insulin-dependent diabetes mellitus. N Engl J Med 1984;310:746-750.
15. Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB: Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus by decreasing hepatic (and extrahepatic) sensitivity to insulin in the absence of insulin waning. Diabetologia 1990;33:52-59.
16. Parillo M, Mura A, Iovine C, Rivellese AA, Iavicoli M, Riccardi G: Prevention of early-morning hyperglycemia in IDDM patients with long-acting zinc insulin. Diabetes Care 1992;15:173-177.
17. Perriello G, De Feo P, Torlone E, Fanelli C, Santeusanio F, Brunetti P, Bolli GB: The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counterregulation and insulin sensitivity. Diabetologia 1991;34:21-28.
18. Bolli GB, Perriello G: Impact of activated glucose counterregulation on insulin requirements in insulin-dependent diabetes mellitus. Horm Metab Res 1990;24(Suppl):87-96.
19. Cryer PE, Binder C, Bolli GB, Cherrington AD, Gale EAM, Gerich JE, Sherwin RS: Hypoglycemia in IDDM. Diabetes 1989;38:1193-1199.
20. Koivisto VA, Yki-Järvinen H, Helve E, Karonen S-L, Pelkonen R: Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII. Diabetes 1986;35:78-82.
21. Gale EAM, Kurtz AB, Tattersall RB: In search of the Somogyi effect. Lancet 1980;2:279-282.
22. Kidson W: The Somogyi effect. Has it ever existed and what harm has it caused? Med J Aust 1993;159:480-482.
23. Masharani U, Karam JH: Diabetes mellitus and hypoglycemia. In: Tierney LMJ, McPhee SJ, Papadakis MA, eds. 2002 Current Medical Diagnosis and Treatment: Adult Ambulatory and Inpatient Management. New York: McGraw-Hill, 2002:1203-1250.
24. Santiago JV, Levandoski LA: Hypoglycemia in patients with type 1 diabetes. In: Lebovitz HE, ed. Therapy for Diabetes Mellitus and Related Disorders. Alexandria, VA: American Diabetes Association, 1998:241-251.
25. Riddle MC, Rosenstock J: Treatment to target study: insulin glargine vs NPH insulin added to oral therapy of type 2 diabetes. Successful control with less nocturnal hypoglycemia [abstract 457-P]. Diabetes 2002;51(Suppl 2):A113.
26. van Staa T, Abenhaim L, Monette J: Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997;50:735-741.
27. Stahl M, Berger W: Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas. Diabet Med 1999;16:586-590.
28. Burge MR, Schade DS: Insulins. Endocrinol Metab Clin North Am 1997;26:575-598.
29. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000;49:2142-2148.
30. Lantus® prescribing information. In: Physicians' Desk Reference®, 57th ed. Montvale, NJ: Medical Economics Co., 2003:735-739.
31. Rosenstock J, Riddle MC: Treatment to target study: timing and frequency of nocturnal hypoglycemia. The value of adding bedtime basal insulin glargine over NPH insulin in insulin-naãve patients with type 2 diabetes on oral agents [abstract 1982-PO]. Diabetes 2002;51(Suppl 2):A482.
32. Yki-Järvinen H, Dressler A, Ziemen M: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000;23:1130-1136.
33. Bernstein RK: The "dawn phenomenon": how do we treat it? Diabetes Care 1985;8:100-101.
34. Riddle MC: Evening insulin strategy. Diabetes Care 1990;13:676-686.
35. Gillies PS, Figgitt DP, Lamb HM: Insulin glargine. Drugs 2000;59:253-260.
36. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T: Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000;23:644-649.
37. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA: Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000;23:639-643.
38. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
39. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
40. Gaede P, Vedel P, Larsen N, Jensen GV, Parving H-H, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393.